Zivo Bioscience director Laith Yaldoo acquires $176,682 in stock

Published 04/04/2025, 13:26
Zivo Bioscience director Laith Yaldoo acquires $176,682 in stock

Laith L. Yaldoo, a director and significant shareholder of Zivo Bioscience, Inc. (NASDAQ:ZIVO), has acquired a substantial number of shares in the company. The micro-cap biotech firm, currently valued at $59.21 million, has seen its stock surge 97% over the past year despite recent volatility. According to the latest SEC filing, Yaldoo purchased a total of 10,080 shares of Zivo Bioscience’s common stock on January 22, 2025, at a price of $17.528 per share. This transaction, valued at approximately $176,682, was executed indirectly through HEP Investments LLC. The shares were acquired in exchange for the release of certain obligations of the company under a License Co-Development Participation Agreement. Following this transaction, Yaldoo holds a total of 554,626 shares in Zivo Bioscience. InvestingPro data shows the stock has taken a significant hit recently, down nearly 8% in the past week, though analysis suggests the current price is near Fair Value. Get access to 10+ additional ProTips and comprehensive insider trading analysis with InvestingPro.

In other recent news, Zivo Bioscience, Inc. has issued new equity shares, raising approximately $1.5 million. The company sold 75,000 shares to an accredited investor at $20.19 per share, while also granting 38,478 shares as restricted stock to non-employee board members under its 2024 Equity Incentive Plan. Additionally, Zivo Bioscience executed an Exchange Program, issuing 78,320 shares to investors in exchange for the cancellation of specific agreements. These transactions were conducted without public offerings, relying on exemptions from the Securities Act of 1933.

In another development, Zivo Bioscience has relocated its principal executive office to Troy, Michigan, from Bloomfield Hills. The new address is 2125 Butterfield Drive, Suite 100, although the company’s contact number remains unchanged. The reasons behind the office relocation were not detailed in the filing. These updates highlight recent logistical and financial activities by Zivo Bioscience.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.